Protein Kinase Inhibitors: all 15,766 studies that test it
Page 15 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- TSN084 Treating Patients With Advanced Malignant TumorsRecruitingNCT06386705Phase 1
- RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT06385873Phase 2
- Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaRecruitingNCT06383728Phase 2
- Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingNCT06382948Phase 3
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingNCT06381661Phase 2
- Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasRecruitingNCT06381570Early Phase 1
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingNCT06380348Phase 3
- Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult SubjectsRecruitingNCT06379958Phase 1
- Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCRecruitingNCT06379087Phase 2
- A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibRecruitingNCT06378892Phase 2
- A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 AlterationsRecruitingNCT06378593Phase 1/2
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Phase 2/3
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruitingNCT06375733Phase 1/2
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
- Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyRecruitingNCT06373458Phase 2
- A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSRecruitingNCT06372717Phase 1
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
- the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibEnrolling by invitationNCT06370416Phase 2
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingNCT06369259Phase 2
- Azenosertib in Uterine Serous Carcinoma: Biomarker StudyRecruitingNCT06369155Phase 2
- A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06368414Phase 2
- MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
- Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06366789Phase 1
- ALPINE: Maintenance Letrozole/AbemaciclibRecruitingNCT06366347Phase 2
- Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerRecruitingNCT06365788Phase 2
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingNCT06364904Phase 3
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingNCT06364267Phase 2
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
- Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
- A Study of SC-0191 in Subjects With Metastatic Colorectal CancerNot yet recruitingNCT06363552Phase 2
- A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR MutationsRecruitingNCT06362980Phase 1
- Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)RecruitingNCT06362707Phase 2
- Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2
- A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy AdultsEnrolling by invitationNCT06360874Phase 1
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
- Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) ArthritisEnrolling by invitationNCT06359665Phase 1
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingNCT06357676Phase 1/2
- A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
- Maintenance Hormonal Therapy and DLBCLNot yet recruitingNCT06355401Phase 2/3
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
- A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06354530Phase 2/3
- Human Models of Selective Insulin Resistance: Alpelisib, Part IRecruitingNCT06354088Phase 1
- A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in ChinaNot yet recruitingNCT06352190Phase 1
- To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingNCT06348134Phase 2
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaNot yet recruitingNCT06343935Phase 4
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingNCT06343064Phase 1/2
- Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerRecruitingNCT06341894Phase 2
- A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Phase 2
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingNCT06339281Phase 2
- A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal MetastasisRecruitingNCT06339242Phase 2
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.Not yet recruitingNCT06339216Phase 2
- Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor FailureNot yet recruitingNCT06336954Phase 2
- Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaRecruitingNCT06333262Phase 2
- Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal MetastasisRecruitingNCT06332287Phase 2
- A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy SubjectsNot yet recruitingNCT06332053Phase 1
- Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1
- A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRADNot yet recruitingNCT06329947Phase 2
- Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological SurgeryRecruitingNCT06329167Phase 4
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLCRecruitingNCT06328049Phase 2
- Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy FailureNot yet recruitingNCT06327698Phase 2
- Avapritinib With Decitabine in Patients With SM-AHNRecruitingNCT06327685Phase 1
- Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingNCT06327269Early Phase 1
- A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular CarcinomaRecruitingNCT06326502Phase 1
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsRecruitingNCT06326411Phase 1
- A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy SubjectsNot yet recruitingNCT06325761Phase 1
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
- Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)Not yet recruitingNCT06323148Phase 3
- Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRCNot yet recruitingNCT06322563Phase 2
- Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate ResectionRecruitingNCT06320990Phase 1
- High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingNCT06319950Phase 2
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingNCT06319820Phase 3
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingNCT06319456Phase 3
- Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRecruitingNCT06317298Not applicable
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingNCT06316960Phase 2
- Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRecruitingNCT06315010Phase 2
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingNCT06313437Phase 1
- Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17Not yet recruitingNCT06312761Phase 1/2
- Phase 2 Study of WGI-0301 for Advanced HCCRecruitingNCT06309485Phase 2
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingNCT06308588Phase 1/2
- Safety Study for the Use of Rapamycin in Children With Familial Adenomatous PolyposisNot yet recruitingNCT06308445Phase 2
- A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06307795Phase 1
- A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.Not yet recruitingNCT06306560Phase 2
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingNCT06303193Phase 1/2
- Pemigatinib + Afatinib in Advanced Refractory Solid TumorsRecruitingNCT06302621Phase 1
- Everolimus Combined With PD-1 in Advanced Colorectal Cancer PatientsNot yet recruitingNCT06301386Phase 2
- A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseRecruitingNCT06300320Phase 2
- PAS-004 in Patients With Advanced Solid TumorsRecruitingNCT06299839Phase 1
- Myeloprotection With Trilaciclib in Pan-cancer PopulationNot yet recruitingNCT06297811Phase 2